TY - JOUR
T1 - Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor
AU - Hu, Wei
AU - Wu, Weiguo
AU - Jim Yeung, Sai Ching
AU - Freedman, Ralph S.
AU - Kavanagh, John J.
AU - Verschraegen, Claire F.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2002
Y1 - 2002
N2 - Since farnesylation by famesyltransferase (FTase) is the first obligatory step in the signaling transduction pathway of ras p21, FTase has been the target of new anticancer treatment modalities. Farnesyl transferase inhibitors (FTIs), a novel class of antitumor drugs that blocks the oncogenic activity of ras, were first developed as therapy for ras-mutated human tumors. FTIs are also capable of inhibiting tumors without ras mutations, while different mechanisms of cell growth inhibition by FTI have been proposed. In cell culture and in animal models, FTIs have been shown to be potent inhibitors of cancer cell growth. We showed that manumycin, a farnesyl pyrophosphate competitive inhibitor, inhibits ovarian and mesothelioma cancer cell growth. To examine the molecular changes after exposure to manumycin, total proteins from treated and untreated 2774 cell line were extracted and separated by two dimensional gel electrophoresis (2-DE) and detected by colloidal coomassie blue staining. The 2-DE was found reliable for comparison of protein profiles before and after manumycin treatment. Two protein spots (spot 1 and 2) appeared after manumycin treatment. Generated peptide peaks were matched by database query (prowl.rockefeller.edu/cgi-bin/ProFound) to a heat shock protein (HSP) and a modified HSP, both with MW 70 KD. The expression status of HSP 70 was confirmed by Western blot and HSP 70 ELISA using an antibody against HSP 70. The expression of HSP70 increased with the length of exposure to, and the dose of, manumycin as demonstrated by ELISA. Increase in HSP70 expression was also observed by Western blot after a 48-hour treatment with manumycin in ovarian cancer cell line OVCAR3 and three other cell cultures derived from samples of patients diagnosed with ovarian cancer and mesothelioma. Out study is the first report demonstrating an up-regulation of HSP 70 in ovarian cancer cell lines and mesothelioma cell cultures after treatment with the FTI, manumycin. This up-regulation of HSP 70 may be a cellular mechanism of cell self-protection against the apoptotic process and cell death, and it may enhance resistance and account for the altered sensitivity of certain cancers to FTIs agents. HSPs may therefore be an important molecular target for drug intervention strategies.
AB - Since farnesylation by famesyltransferase (FTase) is the first obligatory step in the signaling transduction pathway of ras p21, FTase has been the target of new anticancer treatment modalities. Farnesyl transferase inhibitors (FTIs), a novel class of antitumor drugs that blocks the oncogenic activity of ras, were first developed as therapy for ras-mutated human tumors. FTIs are also capable of inhibiting tumors without ras mutations, while different mechanisms of cell growth inhibition by FTI have been proposed. In cell culture and in animal models, FTIs have been shown to be potent inhibitors of cancer cell growth. We showed that manumycin, a farnesyl pyrophosphate competitive inhibitor, inhibits ovarian and mesothelioma cancer cell growth. To examine the molecular changes after exposure to manumycin, total proteins from treated and untreated 2774 cell line were extracted and separated by two dimensional gel electrophoresis (2-DE) and detected by colloidal coomassie blue staining. The 2-DE was found reliable for comparison of protein profiles before and after manumycin treatment. Two protein spots (spot 1 and 2) appeared after manumycin treatment. Generated peptide peaks were matched by database query (prowl.rockefeller.edu/cgi-bin/ProFound) to a heat shock protein (HSP) and a modified HSP, both with MW 70 KD. The expression status of HSP 70 was confirmed by Western blot and HSP 70 ELISA using an antibody against HSP 70. The expression of HSP70 increased with the length of exposure to, and the dose of, manumycin as demonstrated by ELISA. Increase in HSP70 expression was also observed by Western blot after a 48-hour treatment with manumycin in ovarian cancer cell line OVCAR3 and three other cell cultures derived from samples of patients diagnosed with ovarian cancer and mesothelioma. Out study is the first report demonstrating an up-regulation of HSP 70 in ovarian cancer cell lines and mesothelioma cell cultures after treatment with the FTI, manumycin. This up-regulation of HSP 70 may be a cellular mechanism of cell self-protection against the apoptotic process and cell death, and it may enhance resistance and account for the altered sensitivity of certain cancers to FTIs agents. HSPs may therefore be an important molecular target for drug intervention strategies.
KW - Farnesyltransferase inhibitor
KW - Heat shock protein 70
KW - Mesothelioma
KW - Ovarian neoplasms
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=0036254631&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036254631&partnerID=8YFLogxK
M3 - Article
C2 - 12014635
AN - SCOPUS:0036254631
SN - 0250-7005
VL - 22
SP - 665
EP - 672
JO - Anticancer research
JF - Anticancer research
IS - 2 A
ER -